organization · Reporting owner
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avalyn Pharma Inc.
Report date May 01, 2026 · Filed May 01, 2026
Section 16 reporting ended · disclosed 2026-05-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,275,486 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Conversion · Acquired 1,275,486 · Balance 1,275,486 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. |
| Series C-1 Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-01 · Conversion · Disposed 20,482,289 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-01 · Conversion · Disposed 4,060,259 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date.
CARGO Therapeutics, Inc.
Report date November 14, 2023 · Filed November 16, 2023
Section 16 reporting ended · disclosed 2023-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 737,000 |
Reported balance
After 2023-11-14 transaction · row 1
1 source rowRow 1 · 2023-11-14 · Conversion · Acquired 737,000 · Balance 737,000 F1: Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-11-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-14 · Conversion · Disposed 10,000,000 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date.
MBX Biosciences, Inc.
Report date September 16, 2024 · Filed September 17, 2024
Section 16 reporting ended · disclosed 2024-09-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,790,122 |
Ending reported balance
After 2024-09-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-16 · Conversion · Acquired 1,386,335 · Balance 1,386,335 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date. Row 2 · 2024-09-16 · Conversion · Acquired 403,787 · Balance 1,790,122 F2: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-16 · Conversion · Disposed 16,666,666 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-09-16 · Conversion · Disposed 4,854,368 · Balance 0 F2: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date.
F2: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date.
Metsera, Inc.
Report date January 30, 2025 · Filed February 03, 2025
Section 16 reporting ended · disclosed 2025-02-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,857,699 |
Reported balance
After 2025-01-30 transaction · row 1
1 source rowRow 1 · 2025-01-30 · Conversion · Acquired 1,857,699 · Balance 1,857,699 F1: Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-01-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-30 · Conversion · Disposed 4,365,079 · Balance 0 F1: Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.
RayzeBio, Inc.
Report date September 19, 2023 · Filed September 19, 2023
Section 16 reporting ended · disclosed 2023-09-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,557,846 |
Reported balance
After 2023-09-19 transaction · row 1
1 source rowRow 1 · 2023-09-19 · Conversion · Acquired 1,557,846 · Balance 1,557,846 F1: Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date. |
| Series D Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-19 · Conversion · Disposed 1,557,846 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date.
Upstream Bio, Inc.
Report date October 15, 2024 · Filed October 15, 2024
Section 16 reporting ended · disclosed 2024-10-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 894,733 |
Reported balance
After 2024-10-15 transaction · row 1
1 source rowRow 1 · 2024-10-15 · Conversion · Acquired 894,733 · Balance 894,733 F1: Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date. |
| Series B redeemable convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-10-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-10-15 · Conversion · Disposed 852,940 · Balance 0 F1: Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 1, 2026 22:26 UTC | Avalyn Pharma Inc. AVLN · Entity 4662 | ConversionSeries D Convertible Preferred Stock · Derivative | 4,060,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-201863 · ownership.xml · derivative · entry 3 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 211,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:26 UTC | Avalyn Pharma Inc. AVLN · Entity 4662 | ConversionSeries C-1 Convertible Preferred Stock · Derivative | 20,482,289 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-201863 · ownership.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,064,473 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:26 UTC | Avalyn Pharma Inc. AVLN · Entity 4662 | ConversionCommon Stock | 1,275,486 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-201863 · ownership.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,275,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 18:48 UTC | Metsera, Inc. MTSR · Entity 73102 | ConversionSeries B Preferred Stock · Derivative | 4,365,079 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-012574 · ownership.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,857,699 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 18:48 UTC | Metsera, Inc. MTSR · Entity 73102 | ConversionCommon Stock | 1,857,699 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-012574 · ownership.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,857,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 23:21 UTC | Upstream Bio, Inc. UPB · Entity 5743 | ConversionSeries B redeemable convertible preferred stock · Derivative | 852,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-114802 · ownership.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 894,733 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 23:21 UTC | Upstream Bio, Inc. UPB · Entity 5743 | ConversionCommon Stock | 894,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114802 · ownership.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 894,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B redeemable convertible preferred stock automatically converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B redeemable convertible preferred stock had no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:15 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionSeries C Preferred Stock · Derivative | 4,854,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-107489 · ownership.xml · derivative · entry 4 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 403,787 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date. F2 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date. F2 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:15 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionSeries B Preferred Stock · Derivative | 16,666,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-107489 · ownership.xml · derivative · entry 3 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,386,335 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:15 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionCommon Stock | 403,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107489 · ownership.xml · nonDerivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,790,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:15 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionCommon Stock | 1,386,335 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107489 · ownership.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,386,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:19 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | ConversionSeries A-1 Preferred Stock · Derivative | 10,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-064519 · ownership.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 737,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:19 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | ConversionCommon Stock | 737,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-064519 · ownership.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 737,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date. Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 23:41 UTC | RayzeBio, Inc. RYZB · Entity 93779 | ConversionSeries D Preferred Stock · Derivative | 1,557,846 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-048874 · ownership.xml · derivative · entry 2 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,557,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date. Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 23:41 UTC | RayzeBio, Inc. RYZB · Entity 93779 | ConversionCommon Stock | 1,557,846 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-048874 · ownership.xml · nonDerivative · entry 1 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. · CIK 0001903360 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,557,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.